This immunotoxin was achieved by conjugating/fusing the Anti-TNFRSF8 scFv to Pseudomonas exotoxin. It was expressed in CHO and purified with affinity chromatography. The immunotoxin selectively binds to TNFRSF8 overexpressed malignant lymphoma cells. Once bind, the toxin enters cells by receptor-mediated endocytosis. Then PE cleaved fragments the size of Mr 37000 and 27000, the large fragment and finally into the Golgi and elongation factor 2 (EM) combining it glycosylation inactivation, inhibition of protein synthesis, leading to apoptosis. It was designed for treating malignant lymphoma.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.